Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment

Authors

  • Aalok Kumar Internal Medicine Resident, Post-Graduate Year 2, McMaster University, Hamilton, ON
  • Som Dave Mukherjee Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON

DOI:

https://doi.org/10.5489/cuaj.830

Abstract

Ductal carcinoma of the prostate is a rare histologic subtype of
prostate carcinoma. It represents 0.4% to 0.8% of all prostate
cancers and is associated with a poor prognosis. Given the paucity
of cases reported in the literature on ductal prostate carcinoma,
little is known about how this cancer responds to cytotoxic
chemotherapy. We report the case of a 56-year-old male who
presented to our clinic with hemoptysis, cough and hematuria
and was found to have metastatic ductal carcinoma of the prostate.
He was initiated on docetaxel chemotherapy, which has been
previously shown to improve overall survival in patients with
metastatic prostate adenocarcinoma, but has never been studied
in this less common subtype of prostate cancer. To the best of
our knowledge, the following is the first reported case of a patient
with metastatic ductal carcinoma of the prostate responding to
docetaxel chemotherapy.

Downloads

Download data is not yet available.

Author Biographies

Aalok Kumar, Internal Medicine Resident, Post-Graduate Year 2, McMaster University, Hamilton, ON

Som Dave Mukherjee, Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON

Downloads

How to Cite

Kumar, A., & Mukherjee, S. D. (2013). Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment. Canadian Urological Association Journal, 4(2), E50-E54. https://doi.org/10.5489/cuaj.830

Issue

Section

Case Report